LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

2.89 6.25

Overview

Share price change

24h

Current

Min

2.7

Max

2.92

Key metrics

By Trading Economics

Income

-17M

-70M

Sales

547K

47M

Profit margin

-147.345

Employees

560

EBITDA

-17M

-66M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+71.69% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

243M

996M

Previous open

-3.36

Previous close

2.89

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

16 Sept 2025, 17:03 UTC

Major Market Movers

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 Sept 2025, 16:49 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

GD Culture Shares Drop After Deal for Pallas Capital

16 Sept 2025, 16:11 UTC

Major Market Movers

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 Sept 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16 Sept 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 Sept 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 Sept 2025, 21:10 UTC

Acquisitions, Mergers, Takeovers

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 Sept 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 Sept 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16 Sept 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

16 Sept 2025, 20:25 UTC

Earnings

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 Sept 2025, 20:24 UTC

Earnings

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 Sept 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 Sept 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 Sept 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Sept 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 Sept 2025, 18:40 UTC

Acquisitions, Mergers, Takeovers

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 Sept 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 Sept 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 Sept 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 Sept 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 Sept 2025, 16:53 UTC

Earnings

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 Sept 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

16 Sept 2025, 16:15 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Commodities Roundup: Market Talk

16 Sept 2025, 16:09 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Energy Roundup: Market Talk

16 Sept 2025, 16:09 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 Sept 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 Sept 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 Sept 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 Sept 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

71.69% upside

12 Months Forecast

Average 4.67 USD  71.69%

High 5 USD

Low 4 USD

Based on 6 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat